SCHEMBL21058372

SCHEMBL21058372

CCCC(=O)N[C@H]1C(OCc2ccccc2)O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@@H]1OCc1ccccc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 3/20 0.65
▸ POLB P06746 2/20 0.61
▸ KMT2A Q03164 1/20 0.58
▸ TSHR P16473 1/20 0.48
▸ ALDH1A1 P00352 3/20 0.47
▸ CYP2D6 P10635 1/20 0.47
▸ MAPK1 P28482 1/20 0.47
▸ TGM2 P21980 1/20 0.46
▸ SSTR3 P32745 3/20 0.45
▸ SSTR5 P35346 3/20 0.45
▸ SSTR1 P30872 1/20 0.45
▸ SSTR2 P30874 1/20 0.45
▸ SSTR4 P31391 1/20 0.45
▸ CYP3A4 P08684 1/20 0.45
▸ MAPT P10636 1/20 0.45
▸ CYP2C9 P11712 1/20 0.45
▸ CYP2C19 P33261 1/20 0.45
▸ PRKCA P17252 1/20 0.44
▸ AKT1 P31749 1/20 0.44
▸ PTK2 Q05397 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10956036 0.90 LMNA (0.65) LMNAPOLBKMT2ATSHRALDH1A1
SCHEMBL10956041 0.90 LMNA (0.65) LMNAPOLBKMT2ATSHRALDH1A1
SCHEMBL31352990 0.89 LMNA (0.50) LMNAPOLBKMT2ASSTR3SSTR5
SCHEMBL21058370 0.89 LMNA (0.50) LMNAPOLBKMT2ASSTR3SSTR5
SCHEMBL21058359 0.86 LMNA (0.48) LMNAPOLBKMT2ASSTR3SSTR5
SCHEMBL21058380 0.86 LMNA (0.48) LMNAPOLBKMT2ASSTR3SSTR5
SCHEMBL8931470 0.86 POLB (0.79) LMNAPOLBKMT2ATSHRALDH1A1
SCHEMBL21097453 0.86 POLB (0.79) LMNAPOLBKMT2ATSHRALDH1A1
SCHEMBL8931476 0.86 POLB (0.79) LMNAPOLBKMT2ATSHRALDH1A1
SCHEMBL21058366 0.83 SSTR3 (0.47) LMNASSTR3SSTR5SSTR1SSTR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12552823-B2 Glucosamine derivatives and pharmaceutical uses thereof Risen (Suzhou) Pharma Tech Co., Ltd. (CN) 2026-02-17 — — US disclosed
US-20250353870-A1 GLUCOSAMINE DERIVATIVES AND PHARMACEUTICAL USES THEREOF RISEN SUZHOU PHARMA TECH CO LTD (CN) 2025-11-20 — — US disclosed
US-12312378-B2 Glucosamine derivatives for the prevention or treatment of joint disorders Risen (Suzhou) Pharma Tech Co., Ltd. (CN) 2025-05-27 — — US disclosed
US-20240051982-A1 GLUCOSAMINE DERIVATIVES FOR THE PREVENTION OR TREATMENT OF JOINT DISORDERS Risen (Suzhou) Pharma Tech Co., Ltd. (CN) 2024-02-15 — — US disclosed
US-11718636-B2 Glucosamine derivatives for the prevention or treatment of joint disorders Risen (Suzhou) Pharma Tech Co., Ltd. (CN) 2023-08-08 — — US disclosed
US-20230227488-A1 GLUCOSAMINE DERIVATIVES AND PHARMACEUTICAL USES THEREOF RISEN SUZHOU PHARMA TECH CO LTD (CN) 2023-07-20 — — US disclosed
US-11591358-B2 Glucosamine derivatives and pharmaceutical uses thereof Risen (Suzhou) Pharma Tech Co., Ltd. (CN) 2023-02-28 — — US disclosed
CN-115594724-A Glucosamine derivatives for preventing or treating joint diseases 润佳(苏州)医药科技有限公司(CN) 2023-01-13 — — CN disclosed
CN-111971290-B Glucosamine derivatives for preventing or treating joint diseases 润佳(苏州)医药科技有限公司 2022-10-14 — — CN disclosed
US-20210079033-A1 GLUCOSAMINE DERIVATIVES FOR THE PREVENTION OR TREATMENT OF JOINT DISORDERS Risen (Suzhou) Pharma Tech Co., Ltd. (CN) 2021-03-18 — — US disclosed
CN-111971290-A Glucosamine derivatives for preventing or treating joint diseases 润佳(苏州)医药科技有限公司 2020-11-20 — — CN disclosed
US-20190185502-A1 GLUCOSAMINE DERIVATIVES AND PHARMACEUTICAL USES THEREOF RISEN (SUZHOU) PHARMA TECH CO, LTD. (CN) 2019-06-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250353870-A1 GLUCOSAMINE DERIVATIVES AND PHARMACEUTICAL USES THEREOF OGT, UGGT1, GLA LMNA 2743/4885POLB 3798/4885KMT2A 4171/4885
US-20210079033-A1 GLUCOSAMINE DERIVATIVES FOR THE PREVENTION OR TREATMENT OF JOINT DISORDERS OGT, UGGT1, GLA LMNA 2632/4885POLB 4305/4885KMT2A 4314/4885
US-20240051982-A1 GLUCOSAMINE DERIVATIVES FOR THE PREVENTION OR TREATMENT OF JOINT DISORDERS OGT, UGGT1, FUT6 LMNA 3002/4885POLB 4253/4885KMT2A 4082/4885
US-11718636-B2 Glucosamine derivatives for the prevention or treatment of joint disorders OGT, UGGT1, GLA LMNA 2632/4885POLB 4305/4885KMT2A 4314/4885
US-12552823-B2 Glucosamine derivatives and pharmaceutical uses thereof SOST, FUT6, SLC5A1 LMNA 992/4885POLB 2918/4885KMT2A 4311/4885
US-20230227488-A1 GLUCOSAMINE DERIVATIVES AND PHARMACEUTICAL USES THEREOF OGT, UGGT1, GLA LMNA 2743/4885POLB 3798/4885KMT2A 4171/4885
US-20190185502-A1 GLUCOSAMINE DERIVATIVES AND PHARMACEUTICAL USES THEREOF OGT, UGGT1, GLA LMNA 2743/4885POLB 3798/4885KMT2A 4171/4885
US-11591358-B2 Glucosamine derivatives and pharmaceutical uses thereof OGT, UGGT1, GLA LMNA 2743/4885POLB 3798/4885KMT2A 4171/4885
US-12312378-B2 Glucosamine derivatives for the prevention or treatment of joint disorders OGT, UGGT1, FUT6 LMNA 3002/4885POLB 4253/4885KMT2A 4082/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback